Project Grant R01HL184132
Award Date 8/1/26
Completion Date 4/30/30
Dollars Obligated $770K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55454, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $543,957 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how evolving extracellular matrices drive maturation of human pluripotent stem cell-derived cardiomyocytes. The research tests the hypothesis that cardiomyocyte maturation is enhanced through signaling of an evolving extracellular matrix deposited by cardiac fibroblasts in response to dynamic...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $763,046 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a rapid cardiac magnetic resonance imaging (CMR) protocol for heart failure diagnosis. The project addresses barriers to clinical adoption of CMR in heart failure care by reducing examination time from 45–60 minutes to approximately 10 minutes and eliminating the need for...
- The National Heart, Lung, and Blood Institute awarded $657,595 to the Regents of the University of Minnesota on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel statistical methods and computational tools for high-dimensional mediation analysis of cardiovascular disease pathways. The project, supported through NIH's Project Grant mechanism, addresses the challenge of analyzing large-scale molecular datasets, including those from the NHLBI TOPMed...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $231,000 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a risk prediction tool for thromboembolism in heart failure patients without atrial fibrillation. The project will integrate clinical variables with cardiovascular magnetic resonance biomarkers to create the first comprehensive risk stratification score for incident ischemic stroke...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded Duke University $1,532,545 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to analyze the effect of income-based health insurance benefit designs on cardiovascular disease outcomes and disparities among low-income workers. The research examines whether employers' selective provision of more generous health benefits—such as free cardioprotective medicines or low...
- The National Heart, Lung, and Blood Institute awarded the University of Mississippi Medical Center $333,250 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt and pilot-test a home blood pressure monitoring intervention for rural Mississippi. The recipient will modify a validated chronic disease self-management program that combines longitudinal home blood pressure monitoring with a smartphone-delivered virtual agent providing personalized education. The...
- The National Heart, Lung, and Blood Institute awarded $1,577,069 to the Regents of the University of Minnesota on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel therapies for chronic graft-versus-host disease fibrosis using murine models and state-of-the-art molecular techniques. The award funds research into the pathobiology of chronic graft-versus-host disease (CGVHD), specifically investigating how T cell and B cell engagement initiates disease...
- Federal Grant Award Summary The Regents of the University of Minnesota received a $174,528 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through August 31, 2030. This award supports reverse translational research to identify novel treatment targets for atrial myopathy, a condition involving structural, mechanical, or electrophysiological changes in the atria that may...
- The National Institutes of Health's National Heart, Lung and Blood Institute awarded $2,350,623 under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Minnesota on May 1, 2021 for a project concluding on April 30, 2022. The project aims to reduce childhood obesity through an individual randomized controlled trial testing combinations of ecological momentary intervention, home visiting, and video feedback delivered to 510 low-income, racially...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $685,212 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop policy-relevant evidence on the scope and effects of prior authorization (PA) for cardiovascular care. The project quantifies patient exposure to PA for cardiovascular services from 2016 through 2024, identifying which patient groups experience PA barriers and measuring how PA affects service use, care...